et al. Phase I study of single -agent anti -programmed death -1 (MDX -1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of clinical oncology : official journal of the American Society of Clinical Oncol ogy 28, 3167 -3175, doi:10.1200/JCO.2009.26.7609 (2010). 20 A'Hern, R.